SSYS Stock Analysis: Stratasys | NASDAQ
Computer Hardware | NASDAQ, USA | Market Cap: 688m USD | 12M Return: -31.1% | IL0011267213 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.80M
Qual. Beats: 0
Rev. Trend: -95.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Stratasys Ltd. (NASDAQ: SSYS) is a U.S.-based provider of connected polymer-based 3D printing solutions, headquartered in Minnetonka, Minnesota. The company designs and sells additive manufacturing systems, materials, software, and services aimed primarily at business customers rather than hobbyist or consumer markets. Its offerings span multiple 3D printing technologies, including Fused Deposition Modeling (FDM), PolyJet, stereolithography (SLA), and Selective Absorption Fusion (SAF), giving it one of the broadest technology portfolios in the polymer additive manufacturing space.
Stratasys serves a diverse set of end markets, with notable specialization in dental and medical applications (e.g., DentaJet and J3 DentaJet printers, Digital Anatomy Creator, and GrabCAD software for medical users), industrial prototyping and manufacturing, and specialty applications like its TechStyle platform for direct printing on fabrics in the fashion industry. The company also sells consumable materials such as GelMatrix, TissueMatrix, BoneMatrix, and Somos resins, which are required to operate its printers. This hardware-plus-consumables structure is typical of industrial 3D printing vendors and tends to generate recurring revenue tied to the installed base of systems over time.
The company operates within the Information Technology sector, specifically the Technology Hardware, Storage & Peripherals sub-industry, and is classified as a small-cap stock with a market capitalization of approximately $723M USD. It has been publicly listed since 1994, making it one of the longer-tenured public companies in the 3D printing industry, alongside competitors such as 3D Systems and Materialise.
- Dental 3D printing demand lifts consumables revenue and margins
- Industrial FDM system sales track manufacturing capex cycle
- Nano Dimension takeover bid and M&A speculation lift shares
| Net Income: -115.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -0.95 > 1.0 |
| NWC/Revenue: 72.36% < 20% (prev 79.50%; Δ -7.14% < -1%) |
| CFO/TA -0.00 > 3% & CFO -4.58m > Net Income -115.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.1m) vs 12m ago 4.27% < -2% |
| Gross Margin: 42.95% > 18% (prev 43.67%; Δ -0.72% > 0.5%) |
| Asset Turnover: 50.02% > 50% (prev 49.56%; Δ 0.46% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.38 (Total Current Assets 555.5m - Total Current Liabilities 159.5m) / Total Assets 1.05b |
| B: -2.35 (Retained Earnings -2.47b / Total Assets 1.05b) |
| C: -0.10 (EBIT TTM -114.1m / Avg Total Assets 1.09b) |
| D: 3.55 (Book Value of Equity 818.6m / Total Liabilities 230.7m) |
| Altman-Z'' = -2.16 = D |
| DSRI: 1.05 (Receivables 160.4m/157.9m, Revenue 547.3m/564.5m) |
| GMI: 1.02 (GM 43.67% / 42.95%) |
| AQI: 1.00 (AQ_t 0.27 / AQ_t-1 0.27) |
| SGI: 0.97 (Revenue 547.3m / 564.5m) |
| TATA: -0.11 (NI -115.2m - CFO -4.58m) / TA 1.05b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of August 30, 2026, the stock is trading at USD 7.74 with a total of 462,456 shares traded. Over the past week, the price has changed by -2.03%, over one month by -2.64%, over three months by -22.75% and over the past year by -31.08%.
Current recommended Stop Loss: 7.10 (which is 8.3% or 1.7 ATR below the current price).
Stratasys has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SSYS.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12 | 55% |
P/E Forward = 30.1205
P/S = 1.2579
P/B = 0.9202
P/EG = 2.0632
Revenue TTM = 547.3m USD
EBIT TTM = -114.1m USD
EBITDA TTM = -69.8m USD
Long Term Debt = 18.9m USD (estimated: total debt 25.4m - short term 6.55m)
Short Term Debt = 6.55m USD (from shortTermDebt, last quarter)
Debt = 25.4m USD (from shortLongTermDebtTotal, last quarter) (leases 26.7m already included)
Net Debt = -187.1m USD (calculated: Debt 25.4m - CCE 212.5m)
Enterprise Value = 501.3m USD (688.4m + Debt 25.4m - CCE 212.5m)
Interest Coverage Ratio = unknown (Ebit TTM -114.1m / Interest Expense TTM 0.0)
EV/FCF = -20.66x (Enterprise Value 501.3m / FCF TTM -24.3m)
FCF Yield = -4.84% (FCF TTM -24.3m / Enterprise Value 501.3m)
FCF Margin = -4.43% (FCF TTM -24.3m / Revenue TTM 547.3m)
Net Margin = -21.05% (Net Income TTM -115.2m / Revenue TTM 547.3m)
Gross Margin = 42.95% ((Revenue TTM 547.3m - Cost of Revenue TTM 312.2m) / Revenue TTM)
Gross Margin QoQ = 42.39% (prev 42.39%)
Tobins Q-Ratio = 0.48 (Enterprise Value 501.3m / Total Assets 1.05b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 25.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -90.2m (EBIT -114.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.48 (Total Current Assets 555.5m / Total Current Liabilities 159.5m)
Debt / Equity = 0.03 (Debt 25.4m / totalStockholderEquity, last quarter 818.6m)
Debt / EBITDA = 2.68 (negative EBITDA) (Net Debt -187.1m / EBITDA -69.8m)
Debt / FCF = 7.71 (negative FCF - burning cash) (Net Debt -187.1m / FCF TTM -24.3m)
Total Stockholder Equity = 834.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.53% (Net Income -115.2m / Total Assets 1.05b)
RoE = -13.80% (Net Income TTM -115.2m / Total Stockholder Equity 834.9m)
RoCE = -13.37% (EBIT -114.1m / Capital Employed (Equity 834.9m + L.T.Debt 18.9m))
RoIC = -10.38% (negative operating profit) (NOPAT -90.2m / Invested Capital 869.0m)
WACC = 12.84% (E(688.4m)/V(713.8m) * Re(13.31%) + D(25.4m)/V(713.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.31% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 92.43 | Cagr: 10.18%
[DCF] Fair Price = unknown (Cash Flow -24.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.57 | # QB: 0
Revenue Correlation: -95.83 | Revenue CAGR: -5.52% | SUE: -0.27 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.02 | Chg30d=-43.75% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=0.11 | Chg30d=-8.33% | Revisions=+25% | GrowthEPS=-26.7% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=0.19 | Chg30d=+4.17% | Revisions=+0% | GrowthEPS=+70.5% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: +10% (up=4, down=3)